
The FDA has approved Gilead’s Trodelvy therapy for the treatment of metastatic triple-negative breast cancer (TNBC).

Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

